18F-氟昔洛韦与前列腺特异性膜抗原PET/CT在寡转移性前列腺癌管理中的指导作用:AJR专家小组叙事性综述
本文为AJR专家小组叙事性综述,讨论18F-氟昔洛韦与靶向前列腺特异性膜抗原(PSMA)的PET/CT在生化复发后识别早期转移、指导寡转移性前列腺癌管理中的作用。证据支持PSMA PET/CT是识别寡转移性前列腺癌病灶最敏感的影像方法,监管批准后可能成为首选模态。
要点
- 证据支持PSMA PET/CT是识别寡转移性前列腺癌病灶最敏感的影像方法。
- 对于根治性治疗后生化复发的男性,18F-氟昔洛韦或PSMA PET/CT可在较低血清PSA水平识别早期转移。
- PSMA PET/CT监管批准后可能成为首选模态,并推动转移导向治疗的试验发展。
核心结论
- 证据支持PSMA PET/CT是识别寡转移性前列腺癌病灶最敏感的影像模态。
- PSMA PET/CT在监管批准后可能成为首选模态,并推动立体定向消融体部放疗和放射引导手术等转移导向治疗的试验发展。
研究设计与样本
- AJR专家小组叙事性综述,未报告系统检索范围与纳入文献数量。
- 讨论的影像方法包括FDA批准的放射性标记氨基酸类似物18F-氟昔洛韦PET/CT和靶向PSMA的在研放射性标记药物PET/CT。
临床应用与阅片要点
- 对于根治性治疗后生化复发的男性,18F-氟昔洛韦或PSMA PET/CT可在较低血清PSA水平识别早期转移,较传统影像更早可行。
- 放射科医生和核医学医生将在促进寡转移性前列腺癌患者的临床决策和管理中发挥重要作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Twenty-five years ago, oligometastatic disease was proposed as an intermediary clinical state of cancer with unique implications for therapies that may impact cancer evolution and patient outcome. Identification of limited metastases that are potentially amenable to targeted therapies fundamentally depends on the sensitivity of diagnostic tools, including new-generation imaging methods. For men with biochemical recurrence after definitive therapy of the primary prostate cancer, PET/CT using either the FDA-approved radiolabeled amino acid analogue 18F-fluciclovine or investigational radiolabeled agents targeting prostate-specific membrane antigen (PSMA) enables identification of early metastases at lower serum PSA levels than was previously feasible using conventional imaging. Evidence supports PSMA PET/CT as the most sensitive imaging modality available for identifying disease sites in oligometastatic prostate cancer. PSMA PET/CT will likely become the modality of choice after regulatory approval and will drive the development of trials of emerging metastasis-directed therapies such as stereotactic ablative body radiation and radioguided surgery. Indeed, numerous ongoing or planned clinical trials are studying advances in management of oligometastatic prostate cancer based on this heightened diagnostic capacity. In this rapidly evolving clinical environment, radiologists and nuclear medicine physicians will play major roles in facilitating clinical decision making and management of patients with oligometastatic prostate cancer.
引用
- Savir-Baruch B, Choyke PL, Rowe SP, et al. Role of 18F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2021. PMID: 33206564. doi:10.2214/AJR.20.24711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。